Abstract:Objective: The aim of this study was to evaluate the efficacy of a new ultrasound contrast agent, SonoVue, in diagnosis and differential diagnosis of liver lesions.Methods: Thirty-one patients with difficult differential diagnosis or highly suspected for liver lesions on CT, MRI, or conventional US were studied. A dose of 2.4 ml of SonoVue (Bracco, Italy) was infused intravenously within 30 sec. The enhancement level was monitored with a nonlinear scanning mode using an Acuson Sequoia-512 scanner with 6C-2, 4C-1 probes. The comparison examinations were performed with physical examination in all cases and with library examination in 16 patients before and after SonoVue injection. The histopathalogical diagnoses were obtained in 20 patients after SonoVue enhanced US examination. The other diagnoses were confirmed on CT, MRI, and DSA. Twenty patients had malignant liver lesions (16 hepatocellular carcinomas, 4 metastases), while 11 had benign lesions (4 hemangiomas, 2 focal nodular hyperplasias, 5 others).Results: 1) After SonoVue injection, the number of lesions without flow signal intralesions dropped from 15 to 2 with nonlinear scanning modes. 2) The positive diagnoses compared to the histopathalogical diagnoses increased after SonoVue in nonlinear scanning modes (p<0.05). 3) There was no difference in physical examination and library examinations before and after SonoVue injection.Conclusions: SonoVue is useful in visualizing tumor vessel and characterizing liver tumors. It is a safe, efficient ultrasound contrast agent and convenient for use. Objective: The aim of this study was to evaluate the efficacy of a new ultrasound contrast agent, SonoVue, in diagnosis and differential diagnosis of liver lesions. Methods: Thirty-one patients with difficult differential diagnosis or highly suspected for liver lesions on CT, MRI, or conventional US were studied. A dose of 2.4 ml of SonoVue (Bracco, Italy) was infused intravenously within 30 sec. The enhancement level was monitored with a nonlinear scanning mode using an Acuson Sequoia-512 scanner with 6C-2, 4C-1 probes. The comparison examinations were performed with physical examination in all cases and with library examination in 16 patients before and after SonoVue injection. The histopathalogical diagnoses were obtained in 20 patients after SonoVue enhanced US examination. The other diagnoses were confirmed on CT, MRI, and DSA. Twenty patients had malignant liver lesions (16 hepatocellular carcinomas, 4 metastases), while 11 had benign lesions (4 hemangiomas, 2 focal nodular hyperplasias, 5 others). Results: 1) After SonoVue injection, the number of lesions without flow signal intralesions dropped from 15 to 2 with nonlinear scanning modes. 2) The positive diagnoses compared to the histopathalogical diagnoses increased after SonoVue in nonlinear scanning modes (p<0.05). 3) There was no difference in physical examination and library examinations before and after SonoVue injection. Conclusions: SonoVue is useful in visualizing tumor vessel and characterizing liver tumors. It is a safe, efficient ultrasound contrast agent and convenient for use.

Relationship Between Dosage of SonoVue and Image Quality of Liver Occupied Lesions

The Clinical Use of Contrast - Enhanced Gray - Scale Ultrasonography in the Diagnosis of Focal Liver Lesions

Improved differential diagnosis of focal liver disease using SonoVue with nonlinear scanning mode

Contrast-enhanced ultrasound imaging of the liver: a review of the clinical evidence for SonoVue and Sonazoid

Relationship between volume of bladder and contrast-enhanced ultrasound of Sono Vue

A preliminary study of ultrasonic contrast agent SonoVue for liver transplantation

Comparison of SonoVue-enhanced harmonic gray-scale and fundamental color Doppler US in detecting vascularity in liver lesions

The study of correlative analysis between the post-configuration time and enhanced peak intensity with the contrast medium of ultrasound Sono Vue

Diagnostic value and comparison of hepatic cell carcinoma by contrast-enhanced ultrasound with the types of agents: SonoVue and Opeison

Hemodynamics Study of Enhanced Color Flow Images with Ultrasonic Contrast Agent Levovist in Hepatic Focal Lesions

Study of Contrast-Enhanced Ultrasound in Diagnosis of Liver Lesions

Comparison of SonoVue and Sonazoid in Localization of Sentinel Lymph Nodes in Early Breast Cancer Patients

Prospective Assessment of Diagnostic Efficacy and Safety of SonazoidTM and SonoVue® Ultrasound Contrast Agents in Patients with Focal Liver Lesions

Clinical study of chronic rejection of transplant kidney using SonoVue contrast-enhanced ultrasound

Contrast-enhanced ultrasound imaging and quantitative parameters of fluorocarbon:compared with SonoVue

Compared with SonoVue ® LR-5, Sonazoid ® modified LR-5 has better diagnostic sensitivity for hepatocellular carcinoma: a systematic review and meta-analysis

Clinical value of SonoVue contrast-enhanced ultrasonography in the evaluation of chronic renal insufficiency

Focal Liver Lesions - Can Sonovue-Enhanced Ultrasound Be Used To Differentiate Malignant From Benign Lesions?

Influence of Injection Rate of Contrast Medium on Image Quality of Dual Energy Virtual Non-constrast CT of Epigastrium Using Dual Source CT Scanner:A Preliminary Study

Comparative the Clinical Value of Contrast-Enhanced Ultrasonography, Enhancement CT and MRI for Diagnosing of Liver Lesions.

Real-time Contrast Ultrasonography of Focal Liver Lesions